New 'Suicide Switch' CAR-T therapy aims to tame cancer while taming side effects
NCT ID NCT03050190
Summary
This trial is testing a new, fourth-generation version of CAR-T cell therapy for patients whose B-cell cancers have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better hunt and destroy cancer cells, and includes a new safety feature designed to turn the cells off if severe side effects occur. The study aims to find out if this approach is safe and effective for patients, including children over 6 months old.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First People's Hospital of Yunnan
RECRUITINGKunming, Yunnan, 650000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.